跳至主要内容
临床试验/NCT05452668
NCT05452668Unknown不适用

Effectiveness of Laser Therapy of Different Wavelengths in Chemotherapy Induced Oral Mucositis in Children With Acute Lymphoblastic Leukemia

Children's Cancer Hospital Egypt 573572 个研究点 分布在 1 个国家目标入组 51 人开始时间: 2023年5月16日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
51
试验地点
2
主要终点
Pain Assessment

研究概览

简要总结

Introduction: Oral mucositis is one of the most frequent complications associated with chemotherapy, occurring in up to 90% children receiving treatment for cancer. Different treatment modalities have been suggested with inconsistent results. Recently, it has been suggested that the use of laser could reduce the grade of oral mucositis and alleviate the symptoms.

Aim: To evaluate and compare the efficacy between the high (Infrared) wavelength laser and low (red) wavelength laser in management of chemotherapy induced oral mucositis in children with acute lymphoblastic leukemia.

Methods: This study is a randomized, prospective, double-blind trial that will include acute lymphoblastic leukemia inpatients receiving induction chemotherapy between the age of 3 and 14years who develop oral mucositis grade 2 or more. These patients will be randomized by the Clinical Epidemiology unit using a computer-based method into three groups. Group I: will be treated with Laser wavelength 660 nm, group II: will be treated with laser wavelength 970 nm, and group III: will receive mock treatment which is the exact repetition of the treatment modality but without any laser emission. All the patients will follow the hospital standard management for oral mucositis. All patients will be assessed for pain score using CHIMES, oral mucositis using NCI-CTCAE scale V5 on days, 0,4,7 and 11. As well as measuring the duration of the lesion.

详细描述

This study is a randomized, prospective, double-blind trial that will include acute lymphoblastic leukemia inpatients receiving induction chemotherapy between the age of 3 and 14 years who develop oral mucositis grade 2 or more. These patients will be randomized by the Clinical Epidemiology unit using a computer-based method into three groups.

Group I: will be treated with Laser wavelength 660 nm, Group II: will be treated with laser wavelength 970 nm, Group III: will receive mock treatment which is the exact repetition of the treatment modality but without any laser emission.

All the patients will follow the hospital standard management for oral mucositis.

All patients will be assessed for

  1. Pain score using CHIMES,
  2. Oral mucositis using NCI-CTCAE scale V5 on days, 0,4,7 and 11.
  3. Measuring the duration of the lesion.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Double (Participant, Outcomes Assessor)

盲法说明

The outcome evaluator will be a single personnel from the oncology team following up with the case.

入排标准

年龄范围
3 Years 至 14 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Patients with Acute Lymphoblastic Leukemia in the induction therapy phase and have oral mucositis grade 2 or more.
  • Age: 3-14 years old of both genders.
  • No previous treatment with laser.
  • Ability to open mouth for more than 2 cm for the duration of laser application with a level of cooperation (Frankl rating 3 or 4).
  • Patients who still have 10 days in their induction therapy phase or can be followed up for a mininum of 10 days after the development of oral mucositis

排除标准

  • Patients receiving radiotherapy
  • Received oral Cryotherapy or IV keratinocyte growth factor for oral mucositis
  • Patients with unstable clinical condition (e.g. sepsis)
  • Patients who will be withdrawn from participation according to their request or due to loss in follow up

结局指标

主要结局

Pain Assessment

时间窗: 4 days

Assessing the change from baseline pain at day 4. Pain assessment will be done by Children's International Mucositis Evaluation Scale (ChIMES). For children less than 8 years the guardian will assist the child in filling the chart. Pain will be measured on day 0, 4, 7 and 11

次要结局

  • Oral Mucositis Severity:(4 days)

研究者

发起方
Children's Cancer Hospital Egypt 57357
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验